Amgen pricing on Humira biosimilar could benefit payers over patients; how Covid policy could narrow America's political divide

Taking stock of the drug industry, from the lab to the medicine chest

January 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients "Warped incentives baked into the U.S. drug channel will limit savings from biosimilars," said Adam Fein of the Drug Channels Institute. By Ed Silverman STAT+ | FDA may not always require post-approval trials to be enrolled before accelerated approvals An FDA official said Monday that if all other criteria are met, accelerated approval may be granted before post-approval trials are enrolled. By John Wilkerson Opinion: A watershed year for biosimilars — if regulators and policymakers step up 2023 could be a banner year for biosimilars if regulators and policymakers require them to be included in Medicare and other formularies. By Juliana M. Reed Photo by Chip Somodevilla/Getty Images Opinion: How the Biden administration's Covid preparedness policies could narrow America's political divide The White House's Covid Winter Preparedness plan sidesteps the emerging evidence base and President Biden's pledge to "follow the science." By Steven Phillips and Robert C. Gallo and Christian Bréchot Town Hall Ventures' Andy Slavitt on how to invest in Medicaid and health tech Part of Andy Slavitt's mission at Town Hall Ventures is proving that health tech companies can make a viable business working in Medicaid. By Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser